- Home
- LPCN vs EQS Comparison
LPCN vs EQS Comparison
Compare LPCN & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPCN | EQS |
|---|---|---|
| Founded | 1997 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 16.2M |
| IPO Year | 2011 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LPCN | EQS |
|---|---|---|
| Price | $2.10 | $1.00 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 31.2K | 6.7K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,976,677.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $92.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $0.94 |
| 52 Week High | $12.37 | $2.43 |
Technical Indicators
Market Signals| Indicator | LPCN | EQS |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 47.19 |
| Support Level | $2.00 | $0.94 |
| Resistance Level | $2.27 | $1.50 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 0.00 | 53.62 |
Price Performance
Historical ComparisonAbout LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. The company invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.